Table 4.

Mean Baseline Biomarker Values for Patients Enrolled in Part 2 (Intent‐To‐Treat Population)

Biomarker	Ontuxizumab at 8 mg/kg + G/D (n = 139)	Placebo + G/D (n = 70)
Endosialin lymphatic endothelial cell M score	12.8	13.3
Endosialin membranous tumor cell M score	4.2	4.3
Endosialin nonvascular stromal cell M score	18.3	18.7
Endosialin perivascular cell M score	24.1	22.9
Endosialin venous endothelial cell M score	19.1	16.8
Log plasma endosialin, ng/mL	11.463	11.486
PDGFR‐β arterial endothelial cell M score	3.4	3.2
PDGFR‐β capillary endothelial cell M score	30.0	29.0
PDGFR‐β cytoplasmic tumor cell M score	22.7	21.5
PDGFR‐β lymphatic endothelial cell M score	22.0	21.7
PDGFR‐β membranous tumor cell M score	8.3	4.7
PDGFR‐β nonvascular stromal cell M score	21.4	23.4
PDGFR‐β perivascular cell M score	31.8	29.8
PDGFR‐β venous endothelial cell M score	3.6	3.5
Log plasma PDGFR‐β, ng/mL	7.830	7.872

Abbreviations: G/D, gemcitabine and docetaxel; PDGFR‐β, platelet‐derived growth factor receptor β.